Jamshedpur Reporter

Giant-Cell Arteritis Market Insights- DelveInsight

DelveInsight’s “Giant-Cell Arteritis Market Insight, Epidemiology and Market Forecast – 2034” report offers comprehensive insights into giant-cell arteritis epidemiology, current and emerging therapies, market trends, and giant-cell arteritis forecasts.

The giant-cell arteritis market is expected to grow from USD 960 million in 2023, driven by the rising geriatric population, increasing prevalence of cardiovascular disorders, and ongoing clinical advancements by several pharmaceutical companies.

Download the Giant-Cell Arteritis Market report to understand which factors are driving the Giant-Cell Arteritis therapeutic market @ Giant-Cell Arteritis Market Trends.

Giant-cell arteritis, also known as temporal arteritis, is a large-vessel vasculitis that primarily affects the arteries of the head, especially the temporal arteries. The disease is characterized by inflammation that can lead to narrowing and reduced blood flow, with potential consequences such as vision loss and stroke. Its etiology is complex, involving genetic factors as well as environmental triggers. The pathogenesis involves a dual immune response, with IL-6 playing a central role in mediating systemic inflammation.

DelveInsight’s analysis of giant-cell arteritis epidemiology reveals that the US accounted for the highest number of diagnosed giant-cell arteritis prevalent cases in 2023, representing 54% of all diagnosed prevalent cases across the 7MM. The burden of giant-cell arteritis is particularly pronounced among the elderly, with individuals aged 80–89 years constituting approximately 42% of total cases in the US. This underscores the strong association between giant-cell arteritis and the aging population.

Among the European countries, the UK held the highest number of giant-cell arteritis cases, followed by France, while Spain accounted for the lowest number of cases. In Japan, as in Europe, scalp tenderness was the most frequent clinical manifestation, followed by myalgia and fever of unknown origin, highlighting the heterogeneity of clinical presentations across different regions.

Discover evolving trends in the Giant-Cell Arteritis patient pool forecasts @ Giant-Cell Arteritis Epidemiology Analysis.

Giant-cell arteritis diagnosis remains challenging due to the heterogeneity of its clinical presentation. The American College of Rheumatology’s criteria form the diagnostic cornerstone. However, no single test is definitive. Physicians rely on a combination of clinical evaluation, blood tests (ESR, C-reactive protein), imaging modalities such as specialized ultrasound, and the gold-standard temporal artery biopsy to confirm diagnosis and assess vascular involvement.

The current treatment paradigm for giant-cell arteritis is centered on high-dose corticosteroids (Glucocorticoids), particularly prednisone, administered at 40–60 mg daily for three to four weeks, followed by gradual tapering. Immediate initiation of therapy is critical to prevent irreversible complications such as blindness. Despite their efficacy, long-term corticosteroid use is associated with significant adverse effects, including osteoporosis, diabetes, and hypertension, highlighting the need for alternative therapies. Conventional disease-modifying anti-rheumatic drugs (DMARDs), such as azathioprine and mycophenolate mofetil, are sometimes used adjunctively but with limited success.

The therapeutic landscape has evolved with the introduction of Chugai Pharmaceuticals/Roche’s ACTEMRA/ROACTEMRA (tocilizumab), the only approved therapy for the treatment of giant-cell arteritis in 7MM. Tocilizumab is a first-in-class anti-IL-6 receptor monoclonal antibody that showed a significant increase in sustained remission rates when combined with a steroid taper.

In January 2025, Celltrion’s AVTOZMA, a biosimilar to ACTEMRA, received FDA approval for both intravenous and subcutaneous use, expanding access to advanced therapies for giant-cell arteritis and other autoimmune diseases. Furthermore, in April 2025, the FDA and EMA approved AbbVie’s RINVOQ (Upadacitinib) for Giant Cell Arteritis treatment, providing an alternative treatment option that can offer patients with GCA the possibility of tapering off steroids and achieving sustained remission. Upadacitinib is projected to capture the largest market share in the 7MM by 2034.

Several promising therapies are in late-stage clinical development and are expected to reshape the giant-cell arteritis management over the next decade. Novartis’ COSENTYX (secukinumab), a monoclonal antibody targeting interleukin-17A (IL-17A), and Johnson & Johnson/MorphoSys AG’s TREMFYA (guselkumab), an IL-23p19 inhibitor, are advancing through clinical development. CSL/Kiniksa’s mavrilimumab, a granulocyte-macrophage colony-stimulating factor receptor antagonist, further reflects the diversification of therapeutic targets in giant-cell arteritis.

Discover recent advancements in the Giant-Cell Arteritis treatment landscape @ Giant-Cell Arteritis Recent Developments.

Looking ahead, the giant-cell arteritis market is expected to benefit from continued innovation and an aging population. As companies advance novel therapeutics and address longstanding unmet needs, the market is set for transformation, offering improved outcomes for patients at risk of this autoimmune complication. However, challenges such as delays in diagnosis, risk of serious complications, economic burden, and gaps in disease understanding continue to impact the market’s trajectory. For industry participants and healthcare providers, staying abreast of these developments is essential for optimizing treatment strategies and capitalizing on emerging opportunities in the giant-cell arteritis market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Giant-Cell Arteritis

4. Giant-Cell Arteritis Market Overview at a Glance

5. Disease Background and Overview

6. Diagnosis of Giant-Cell Arteritis

7. Diagnostic Guidelines

8. Treatment of Giant-Cell Arteritis

9. Treatment Guidelines

10. Epidemiology and Market Forecast Methodology

11. Giant-Cell Arteritis Epidemiology and Patient Population

12. Giant-Cell Arteritis Patient Journey

13. Giant-Cell Arteritis Marketed Therapies

14. Giant-Cell Arteritis Emerging Therapies

15. Giant-Cell Arteritis: Market Analysis

16. Giant-Cell Arteritis Unmet Needs

17. SWOT Analysis

18. KOL Views

19. Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports:

Giant-Cell Arteritis Pipeline Insight

Giant-Cell Arteritis Pipeline Insight provides comprehensive insights about the Giant-Cell Arteritis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Giant-Cell Arteritis companies, including Novartis, AbbVie, XOMA, Kiniksa Pharmaceuticals, Ltd., Eli Lilly and Company, Janssen Biotech, and Dr Reddy’s Laboratories, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services